Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Min Mao

Showing results (591-600 of 618) with videos related to

Pageof 62
Sort By:
Signal Transduction and Targeted Therapy|February 2, 2022
EPHA2 mediates PDGFA activity and functions together with PDGFRA as prognostic marker and therapeutic target in glioblastomaQu-Jing Gai, Zhen Fu, Jiang He, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 27, 2020
Effect of rhG-CSF Combined With Decitabine Prophylaxis on Relapse of Patients With High-Risk MRD-Negative AML After HSCT: An Open-Label, Multicenter, Randomized Controlled TrialLei Gao, Yanqi Zhang, Sanbin Wang, et al.
British Journal of Haematology|May 27, 2020
Development and validation of a prediction model (AHC) for early identification of refractory thrombotic thrombocytopenic purpura using nationally representative dataRuo-Yun Gui, Qiu-Sha Huang, Xuan Cai, et al.
The Lancet. Oncology|November 28, 2017
Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 studyWen-Zhao Zhong, Qun Wang, Wei-Min Mao, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 7, 2018
The Unique Spatial-Temporal Treatment Failure Patterns of Adjuvant Gefitinib Therapy: A Post Hoc Analysis of the ADJUVANT Trial (CTONG 1104)Song-Tao Xu, Jun-Jie Xi, Wen-Zhao Zhong, et al.
Science Translational Medicine|April 8, 2026
Pharmacological activation of WASp potentiates macrophage phagocytosis and enhances ibrutinib efficacy against mouse models of brain tumorsYue Cheng, Tianran Li, Mengru Wang, et al.
Nature Communications|July 7, 2021
Twelve-month specific IgG response to SARS-CoV-2 receptor-binding domain among COVID-19 convalescent plasma donors in WuhanCesheng Li, Ding Yu, Xiao Wu, et al.
Cell Research|July 9, 2021
Pericytes augment glioblastoma cell resistance to temozolomide through CCL5-CCR5 paracrine signalingXiao-Ning Zhang, Kai-Di Yang, Cong Chen, et al.
The Journal of Pathology|June 20, 2022
A map of the spatial distribution and tumour-associated macrophage states in glioblastoma and grade 4 IDH-mutant astrocytomaWen Yin, Yi-Fang Ping, Fei Li, et al.
Cancer Research|September 25, 2025
TRIM49 Deficiency Stabilizes a Galectin-3/EGR1 Transcriptional Complex that Drives Invasiveness of Gastric AdenocarcinomaZhong-Yi Qin, Lin-Rong Che, Shuoran Tian, et al.
Pageof 62

Showing results (591-600 of 618) with videos related to

Sort By:
Pageof 62
Signal Transduction and Targeted Therapy|February 2, 2022
EPHA2 mediates PDGFA activity and functions together with PDGFRA as prognostic marker and therapeutic target in glioblastomaQu-Jing Gai, Zhen Fu, Jiang He, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 27, 2020
Effect of rhG-CSF Combined With Decitabine Prophylaxis on Relapse of Patients With High-Risk MRD-Negative AML After HSCT: An Open-Label, Multicenter, Randomized Controlled TrialLei Gao, Yanqi Zhang, Sanbin Wang, et al.
British Journal of Haematology|May 27, 2020
Development and validation of a prediction model (AHC) for early identification of refractory thrombotic thrombocytopenic purpura using nationally representative dataRuo-Yun Gui, Qiu-Sha Huang, Xuan Cai, et al.
The Lancet. Oncology|November 28, 2017
Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 studyWen-Zhao Zhong, Qun Wang, Wei-Min Mao, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 7, 2018
The Unique Spatial-Temporal Treatment Failure Patterns of Adjuvant Gefitinib Therapy: A Post Hoc Analysis of the ADJUVANT Trial (CTONG 1104)Song-Tao Xu, Jun-Jie Xi, Wen-Zhao Zhong, et al.
Science Translational Medicine|April 8, 2026
Pharmacological activation of WASp potentiates macrophage phagocytosis and enhances ibrutinib efficacy against mouse models of brain tumorsYue Cheng, Tianran Li, Mengru Wang, et al.
Nature Communications|July 7, 2021
Twelve-month specific IgG response to SARS-CoV-2 receptor-binding domain among COVID-19 convalescent plasma donors in WuhanCesheng Li, Ding Yu, Xiao Wu, et al.
Cell Research|July 9, 2021
Pericytes augment glioblastoma cell resistance to temozolomide through CCL5-CCR5 paracrine signalingXiao-Ning Zhang, Kai-Di Yang, Cong Chen, et al.
The Journal of Pathology|June 20, 2022
A map of the spatial distribution and tumour-associated macrophage states in glioblastoma and grade 4 IDH-mutant astrocytomaWen Yin, Yi-Fang Ping, Fei Li, et al.
Cancer Research|September 25, 2025
TRIM49 Deficiency Stabilizes a Galectin-3/EGR1 Transcriptional Complex that Drives Invasiveness of Gastric AdenocarcinomaZhong-Yi Qin, Lin-Rong Che, Shuoran Tian, et al.
Pageof 62